Sagimet Biosciences - Public Comps and Valuation Multiples

Sagimet Biosciences Overview

About Sagimet Biosciences

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Founded

2006

HQ

Employees

Website

sagimet.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

Last FY Revenue n/a

LTM EBITDA -$59.0M

EV

$102M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Sagimet Biosciences Financials

As of September 2025, Sagimet Biosciences reported last 12-month EBITDA of -$59.0M.

In the same period, Sagimet Biosciences achieved -$52.5M in LTM net income.

See Sagimet Biosciences valuation multiples based on analyst estimates

Sagimet Biosciences P&L

In the most recent fiscal year, Sagimet Biosciences reported EBITDA of -$54.5M.

Sagimet Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Sagimet Biosciences valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	n/a	XXX	n/a	XXX	XXX	XXX
Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
Gross Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA	-$59.0M	XXX	-$54.5M	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBIT	-$59.5M	XXX	-$54.5M	XXX	XXX	XXX
EBIT Margin	n/a	XXX	n/a	XXX	XXX	XXX
Net Profit	-$52.5M	XXX	-$45.6M	XXX	XXX	XXX
Net Margin	n/a	XXX	n/a	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Sagimet Biosciences including revenue, profitability, and margin analysis across different time periods. EBITDA for the last twelve months was -$59.0M.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$59.0M	Analyst estimates available to subscribers	-$54.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$59.5M	Analyst estimates available to subscribers	-$54.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$52.5M	Analyst estimates available to subscribers	-$45.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Sagimet Biosciences

This financial data table provides comprehensive performance metrics for Sagimet Biosciences, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

The company achieved -$59.0M in EBITDA over the last twelve months.
Net income over the last twelve months reached -$52.5M.

Fiscal Year Performance

Fiscal year EBITDA was -$54.5M.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Sagimet Biosciences. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Sagimet Biosciences Stock Performance

Sagimet Biosciences has current market cap of $227M, and EV of $102M.

Market Cap Evolution

Sagimet Biosciences Stock Data

As of October 2, 2025, Sagimet Biosciences's stock price is $7.

See Sagimet Biosciences trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$102M	$227M	XXX	XXX	XXX	XXX	$-1.62

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Sagimet Biosciences Valuation Multiples

Sagimet Biosciences's trades at 50.9x EV/Revenue multiple, and -1.9x EV/EBITDA.

See valuation multiples for Sagimet Biosciences and 15K+ public comps

Sagimet Biosciences Financial Valuation Multiples

As of October 2, 2025, Sagimet Biosciences has market cap of $227M and EV of $102M.

Equity research analysts estimate Sagimet Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Sagimet Biosciences has a P/E ratio of -4.3x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$227M	XXX	$227M	XXX	XXX	XXX
EV (current)	$102M	XXX	$102M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	50.9x	XXX	XXX	XXX
EV/EBITDA	-1.7x	XXX	-1.9x	XXX	XXX	XXX
EV/EBIT	-1.7x	XXX	-1.9x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	-4.3x	XXX	-5.0x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-2.4x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Sagimet Biosciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Sagimet Biosciences Margins & Growth Rates

Sagimet Biosciences's revenue per employee in the last FY averaged n/a, while opex per employee averaged $3.9M for the same period.

Sagimet Biosciences's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Sagimet Biosciences's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Sagimet Biosciences and other 15K+ public comps

Sagimet Biosciences Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	39%	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$3.9M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	n/a	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial